Rotavirus
Conditions
Keywords
Healthy Japanese infants, Safety, Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) vaccine, Vaccination, Oral HRV liquid vaccine, Immunogenicity
Brief summary
The purpose of this study is to evaluate the immunogenicity and safety of the diphtheria, tetanus, pertussis and inactivated poliovirus (DPT-IPV) vaccine Squarekids administered with or without the GSK Biologicals' liquid Rotarix (HRV) vaccine, in healthy Japanese infants aged 6 - 12 weeks. GSK Biologicals' liquid HRV vaccine Rotarix is licensed in Japan since 2011. Although the concomitant administration of GSK Biologicals' DTP-IPV vaccine has been evaluated during the clinical development of the HRV vaccine, the vaccine differed in composition and route of administration from the DPT-IPV vaccine Squarekids manufactured in Japan. Hence, as requested by the Japanese regulatory authorities, this post-licensure study will evaluate the immunogenicity of the DPT-IPV vaccine manufactured in Japan when co-administered with the liquid HRV vaccine
Detailed description
This study is a phase IV, open-label, randomised, controlled, multi-centric, single-country study with two parallel groups. Subjects in the co-administration group will be administered the DPT-IPV vaccine according to a 3, 4, 6 month schedule and the liquid HRV vaccine according to a 2, 3 month schedule. Subjects in the staggered group will be administered the DPT-IPV vaccine according to a 3, 4.5, 6 month schedule and the liquid HRV vaccine according to a 2, 3.5 month schedule. The intended duration of the study, per subject, is 5 months. A sub-cohort of subjects (HRV Immunogenicity sub-cohort) from both the study groups will include the first 73 subjects enrolled into the study to assess the serum anti-RV IgA seropositivity and Geometric Mean Concentrations (GMC).
Interventions
BIOLOGICALSquarekids
Three doses administered subcutaneously in the upper arm or thigh
BIOLOGICALRotarix
Two doses administered orally
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Weeks to 12 Weeks
Healthy volunteers
Yes
Inclusion criteria
* Subjects' parent(s)/ Legally Acceptable Representative(s) \[LAR(s)\] who, in the opinion of the investigator can and will comply with the requirements of the protocol. * A male or female between, and including, 6 and 12 weeks of age at the time of the first dose of HRV vaccination. * Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure. * Healthy subjects as established by medical history and clinical examination before entering into the study. * Born full-term as per the delivery records.
Exclusion criteria
* Child in care. * Use of any investigational or non-registered product other than the study vaccines within 30 days before the first dose of study vaccine, or planned use during the study period. * Chronic administration of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone (≥ 0.5 mg/kg/day, or equivalent). Inhaled and topical steroids are allowed. * Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. * Administration of long-acting immune-modifying drugs at any time during the study period. * Planned administration/administration of a vaccine not fore-seen by the study protocol within the period starting 30 days before the first dose of HRV vaccine administration and ending at Visit 7, with the exception of other routinely administered vaccines like PCV, Hib, BCG, hepatitis B, meningococcal vaccine and inactivated influenza vaccines, which are allowed at any time during the study, if administered at sites different from the sites used to administer the DPT-IPV vaccine. * Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product. * Uncorrected congenital malformation of the gastrointestinal tract that would predispose for Intussusception (IS). * History of IS. * Family history of congenital or hereditary immunodeficiency. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * Major congenital defects or serious chronic illness. * Previous vaccination against rotavirus, diphtheria, tetanus, pertussis and/ or poliovirus. * Previous confirmed occurrence of RV GE, diphtheria, tetanus, pertussis, and/ or polio disease. * GE within 7 days preceding the HRV vaccine administration. * History of any reaction or hypersensitivity likely to be exacerbated by any component of the HRV or DPT-IPV vaccines. * Hypersensitivity to latex. * History of any neurological disorders or seizures. * History of SCID. * Acute disease and/or fever at the time of enrollment. * Fever is defined as temperature ≥ 37.5°C /99.5°F on oral, axillary or tympanic setting, or ≥ 38.0°C /100.4°F on rectal setting. * Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Greater Than or Equal to (≥) the Cut-off Value | One month post third dose of DTP-IPV vaccine (At Month 5) | Percentage of subjects with anti-D and anti-T antibody concentrations ≥ 0.1 international units per milliliter (IU/mL). |
| Percentage of Subjects With Anti-pertussis Toxoid (Anti-PT) and Anti-filamentous Haemagglutinin (Anti-FHA) Antibody Concentrations ≥ the Cut-off Value | One month post third dose of DTP-IPV vaccine (At Month 5) | Percentage of subjects with anti-PT and anti-FHA antibody concentrations ≥ 10 IU/mL. |
| Percentage of Subjects With Anti-poliovirus Serotypes 1, 2 and 3 (Anti-polio 1, 2 and 3) Antibody Titers ≥ the Cut-off Value | One month post third dose of DTP-IPV vaccine (At Month 5) | Percentage of subjects with anti-polio 1, 2 and 3 antibody titers ≥ 8 estimated doses 50% (ED50). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anti-polio 1, 2 and 3 Antibodies Titers to Evaluate Immunogenicity | One month post third dose of DTP-IPV vaccine (At Month 5) | Titers of anti-polio 1, 2 and 3 were assessed by Neutralisation Assay (NEU) and presented as Geometric Mean Titers (GMTs). The assay cut-off was 8 ED50. |
| Anti-PT and Anti-FHA Antibody Concentrations to Evaluate Immunogenicity | One month post third dose of DTP-IPV vaccine (At Month 5) | Concentrations of anti-PT and anti-FHA antibodies were assessed by ELISA, presented as GMCs and expressed in IU/mL. The assay cut-offs for anti-PT and anti-FHA antibody concentrations were 2.693 IU/mL and 2.046 IU/mL respectively. |
| Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | During the 8-day (Days 0-7) follow-up period after each dose of liquid HRV vaccine | Assessed solicited general AEs were fever (defined as axillary temperature ≥ 37.5 degrees Celsius \[°C\]), irritability/fussiness, diarrhoea (defined as passage of three or more looser than normal stools within a day), vomiting (defined as one or more episodes of forceful emptying of partially digested stomach contents ≥ 1 hour after feeding within a day), loss of appetite and cough/runny nose. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. |
| Number of Subjects With Any Solicited Local AEs After First Dose of DTP-IPV Vaccine | During the 8-day (Days 0-7) follow-up period after first dose of DTP-IPV vaccine | Assessed solicited local AEs were pain, redness and swelling at injection site. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. |
| Percentage of Seropositive Subjects for Serum Anti-rotavirus (Anti-RV) Immunoglobulin A (IgA) Antibodies in a Sub-cohort of Subjects | One month post second dose of liquid HRV vaccine (At Month 2 for the Co-administration Group and at Month 2.5 for the Staggered Group) | A seropositive subject for serum anti-RV IgA antibodies was defined as a subject with anti-RV IgA antibody concentration ≥ the seropositivity cut-off value of 20 units per milliliter (U/mL). Immunogenicity of the liquid HRV vaccine in terms of serum anti-RV IgA antibody seropositivity was assessed in a sub-cohort of subjects (HRV immunogenicity sub-cohort) which included the first 73 subjects enrolled into each of the 2 study groups. |
| Number of Subjects With Any Unsolicited AEs After Each Dose of Liquid HRV Vaccine | During the 31-day (Days 0-30) follow-up period after each dose of liquid HRV vaccine | Unsolicited AEs were defined as any AE reported in addition to those solicited during the clinical study and any solicited AE with onset outside the specified period of follow-up for solicited AEs. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. |
| Number of Subjects With Any Unsolicited AE After First Dose of DTP-IPV Vaccine | During the 31-day (Days 0-30) follow-up period after first dose of DTP-IPV vaccine | Unsolicited AEs were defined as any AE reported in addition to those solicited during the clinical study and any solicited AE with onset outside the specified period of follow-up for solicited AEs. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. |
| Number of Subjects With Any Serious Adverse Events (SAEs) | During the entire study period (from Day 0 to Month 5) | Assessed SAEs included any untoward medical occurrence that resulted in death, was life threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. |
| Number of Subjects With Any Solicited General AEs After First Dose of DTP-IPV Vaccine | During the 8-day (Days 0-7) follow-up period after first dose of DTP-IPV vaccine | Assessed solicited general AEs were drowsiness, fever (defined as axillary temperature ≥ 37.5 °C), irritability/fussiness and loss of appetite. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination. |
| Serum Anti-RV IgA Antibody Concentration to Evaluate Immunogenicity in a Sub-cohort of Subjects | One month post second dose of liquid HRV vaccine (At Month 2 for the Co-administration Group and at Month 2.5 for the Staggered Group) | Concentration of serum anti-RV IgA antibody was assessed by Enzyme Linked Immunosorbent Assay (ELISA) and expressed as geometric mean concentration (GMC) in U/mL. The assay cut-off was 20 U/mL. Immunogenicity of the liquid HRV vaccine in terms of serum anti-RV IgA antibody GMC was assessed in a sub-cohort of subjects (HRV immunogenicity sub-cohort) which included the first 73 subjects enrolled into each of the 2 study groups. |
| Anti-D and Anti-T Antibody Concentrations to Evaluate Immunogenicity | One month post third dose of DTP-IPV vaccine (At Month 5) | Concentrations of anti-D and anti-T antibodies were assessed by ELISA, presented as GMCs and expressed in IU/mL. The assay cut-off for anti-D and anti-T antibody concentrations was 0.1 IU/mL. |
Countries
Japan
Participant flow
Pre-assignment details
Out of the 292 subjects enrolled in the study, the first 73 subjects enrolled into each of the 2 study groups (total of 146 subjects) were allocated to the HRV immunogenicity sub-cohort to evaluate immunogenicity of the liquid HRV vaccine.
Participants by arm
| Arm | Count |
|---|---|
| Co-administration Group Subjects aged 6 to 12 weeks who received the DPT-IPV vaccine according to a 3, 4, 6 month schedule and the liquid HRV vaccine according to a 2, 3 month schedule. The HRV vaccine was administered orally while the DTP-IPV vaccine was administered subcutaneously in the upper arm or upper thigh. | 147 |
| Staggered Group Subjects aged 6 to 12 weeks who received the DPT-IPV vaccine according to a 3, 4.5, 6 month schedule and the liquid HRV vaccine according to a 2, 3.5 month schedule. The HRV vaccine was administered orally while the DTP-IPV vaccine was administered subcutaneously in the upper arm or upper thigh. | 145 |
| Total | 292 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | No benefit to be obtained by continuing | 0 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 0 |
Baseline characteristics
| Characteristic | Total | Staggered Group | Co-administration Group |
|---|---|---|---|
| Age, Continuous Weeks of age at Dose 1 of DPT-IPV | 14 Weeks STANDARD_DEVIATION 1.1 | 13.9 Weeks STANDARD_DEVIATION 1 | 14 Weeks STANDARD_DEVIATION 1.1 |
| Age, Continuous Weeks of age at Dose 1 of HRV | 9.5 Weeks STANDARD_DEVIATION 1.1 | 9.4 Weeks STANDARD_DEVIATION 1.1 | 9.5 Weeks STANDARD_DEVIATION 1.1 |
| Age, Continuous Weeks of age at Dose 2 of DPT-IPV | 19.2 Weeks STANDARD_DEVIATION 1.5 | 20 Weeks STANDARD_DEVIATION 1.4 | 18.5 Weeks STANDARD_DEVIATION 1.2 |
| Age, Continuous Weeks of age at Dose 2 of HRV | 14.7 Weeks STANDARD_DEVIATION 1.4 | 15.5 Weeks STANDARD_DEVIATION 1.3 | 14 Weeks STANDARD_DEVIATION 1.1 |
| Age, Continuous Weeks of age at Dose 3 of DPT-IPV | 24.4 Weeks STANDARD_DEVIATION 1.9 | 25 Weeks STANDARD_DEVIATION 1.9 | 23.7 Weeks STANDARD_DEVIATION 1.8 |
| Race/Ethnicity, Customized Asian - Japanese Heritage | 292 Participants | 145 Participants | 147 Participants |
| Sex: Female, Male Female | 137 Participants | 65 Participants | 72 Participants |
| Sex: Female, Male Male | 155 Participants | 80 Participants | 75 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 147 | 0 / 145 |
| other Total, other adverse events | 141 / 147 | 143 / 145 |
| serious Total, serious adverse events | 4 / 147 | 5 / 147 |
Outcome results
Primary
Percentage of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Greater Than or Equal to (≥) the Cut-off Value
Percentage of subjects with anti-D and anti-T antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).
Time frame: One month post third dose of DTP-IPV vaccine (At Month 5)
Population: Analysis was performed on According-to-Protocol (ATP) cohort which included all subjects who complied with vaccination schedules of DPT-IPV and HRV vaccines, complied with the blood sampling schedule and for whom immunogenicity data was available for at least for one antigen of the DPT-IPV vaccine at Visit 7 (Month 5) sampling time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Co-administration Group | Percentage of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Greater Than or Equal to (≥) the Cut-off Value | Anti-D antibody ≥ 0.1 IU/mL | 100 Percentage of subjects |
| Co-administration Group | Percentage of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Greater Than or Equal to (≥) the Cut-off Value | Anti-T antibody ≥ 0.1 IU/mL | 98.6 Percentage of subjects |
| Staggered Group | Percentage of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Greater Than or Equal to (≥) the Cut-off Value | Anti-D antibody ≥ 0.1 IU/mL | 100 Percentage of subjects |
| Staggered Group | Percentage of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations Greater Than or Equal to (≥) the Cut-off Value | Anti-T antibody ≥ 0.1 IU/mL | 99.3 Percentage of subjects |
Comparison: Difference between Co-administration Group minus Staggered Group in terms of percentage of subjects with anti-D antibody concentration ≥ 0.1 IU/mL.95% CI: [-2.66, 2.74]
Comparison: Difference between Co-administration Group minus Staggered Group in terms of percentage of subjects with anti-T antibody concentration ≥ 0.1 IU/mL.95% CI: [-4.39, 2.71]
Primary
Percentage of Subjects With Anti-pertussis Toxoid (Anti-PT) and Anti-filamentous Haemagglutinin (Anti-FHA) Antibody Concentrations ≥ the Cut-off Value
Percentage of subjects with anti-PT and anti-FHA antibody concentrations ≥ 10 IU/mL.
Time frame: One month post third dose of DTP-IPV vaccine (At Month 5)
Population: Analysis was performed on ATP cohort which included all subjects who complied with vaccination schedules of DPT-IPV and HRV vaccines, complied with the blood sampling schedule and for whom immunogenicity data was available for at least for one antigen of the DPT-IPV vaccine at Visit 7 (Month 5) sampling time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Co-administration Group | Percentage of Subjects With Anti-pertussis Toxoid (Anti-PT) and Anti-filamentous Haemagglutinin (Anti-FHA) Antibody Concentrations ≥ the Cut-off Value | Anti-PT antibody ≥ 10 IU/mL | 95.7 Percentage of subjects |
| Co-administration Group | Percentage of Subjects With Anti-pertussis Toxoid (Anti-PT) and Anti-filamentous Haemagglutinin (Anti-FHA) Antibody Concentrations ≥ the Cut-off Value | Anti-FHA antibody ≥ 10 IU/mL | 100 Percentage of subjects |
| Staggered Group | Percentage of Subjects With Anti-pertussis Toxoid (Anti-PT) and Anti-filamentous Haemagglutinin (Anti-FHA) Antibody Concentrations ≥ the Cut-off Value | Anti-PT antibody ≥ 10 IU/mL | 92.8 Percentage of subjects |
| Staggered Group | Percentage of Subjects With Anti-pertussis Toxoid (Anti-PT) and Anti-filamentous Haemagglutinin (Anti-FHA) Antibody Concentrations ≥ the Cut-off Value | Anti-FHA antibody ≥ 10 IU/mL | 100 Percentage of subjects |
Comparison: Difference between Co-administration Group minus Staggered Group in terms of percentage of subjects with anti-PT antibody concentration ≥ 10 IU/mL.95% CI: [-2.7, 9.12]
Comparison: Difference between Co-administration Group minus Staggered Group in terms of percentage of subjects with anti-FHA antibody concentration ≥ 10 IU/mL.95% CI: [-2.66, 2.72]
Primary
Percentage of Subjects With Anti-poliovirus Serotypes 1, 2 and 3 (Anti-polio 1, 2 and 3) Antibody Titers ≥ the Cut-off Value
Percentage of subjects with anti-polio 1, 2 and 3 antibody titers ≥ 8 estimated doses 50% (ED50).
Time frame: One month post third dose of DTP-IPV vaccine (At Month 5)
Population: Analysis was performed on ATP cohort which included all subjects who complied with vaccination schedules of DPT-IPV and HRV vaccines, complied with the blood sampling schedule and for whom immunogenicity data was available for at least for one antigen of the DPT-IPV vaccine at Visit 7 (Month 5) sampling time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Co-administration Group | Percentage of Subjects With Anti-poliovirus Serotypes 1, 2 and 3 (Anti-polio 1, 2 and 3) Antibody Titers ≥ the Cut-off Value | Anti-Polio 1 antibody ≥ 8 ED50 | 100 Percentage of subjects |
| Co-administration Group | Percentage of Subjects With Anti-poliovirus Serotypes 1, 2 and 3 (Anti-polio 1, 2 and 3) Antibody Titers ≥ the Cut-off Value | Anti-Polio 2 antibody ≥ 8 ED50 | 100 Percentage of subjects |
| Co-administration Group | Percentage of Subjects With Anti-poliovirus Serotypes 1, 2 and 3 (Anti-polio 1, 2 and 3) Antibody Titers ≥ the Cut-off Value | Anti-Polio 3 antibody ≥ 8 ED50 | 100 Percentage of subjects |
| Staggered Group | Percentage of Subjects With Anti-poliovirus Serotypes 1, 2 and 3 (Anti-polio 1, 2 and 3) Antibody Titers ≥ the Cut-off Value | Anti-Polio 1 antibody ≥ 8 ED50 | 100 Percentage of subjects |
| Staggered Group | Percentage of Subjects With Anti-poliovirus Serotypes 1, 2 and 3 (Anti-polio 1, 2 and 3) Antibody Titers ≥ the Cut-off Value | Anti-Polio 2 antibody ≥ 8 ED50 | 100 Percentage of subjects |
| Staggered Group | Percentage of Subjects With Anti-poliovirus Serotypes 1, 2 and 3 (Anti-polio 1, 2 and 3) Antibody Titers ≥ the Cut-off Value | Anti-Polio 3 antibody ≥ 8 ED50 | 99.2 Percentage of subjects |
Comparison: Difference between Co-administration Group minus Staggered Group in terms of percentage of subjects with anti-polio 1 seroprotective titres ≥ 8 ED50.95% CI: [-2.68, 2.74]
Comparison: Difference between Co-administration Group minus Staggered Group in terms of percentage of subjects with anti-polio 2 seroprotective titres ≥ 8 ED50.95% CI: [-2.92, 2.95]
Comparison: Difference between Co-administration Group minus Staggered Group in terms of percentage of subjects with anti-polio 3 seroprotective titres ≥ 8 ED50.95% CI: [-2.04, 4.47]
Secondary
Anti-D and Anti-T Antibody Concentrations to Evaluate Immunogenicity
Concentrations of anti-D and anti-T antibodies were assessed by ELISA, presented as GMCs and expressed in IU/mL. The assay cut-off for anti-D and anti-T antibody concentrations was 0.1 IU/mL.
Time frame: One month post third dose of DTP-IPV vaccine (At Month 5)
Population: Analysis was performed on ATP cohort which included all subjects who complied with vaccination schedules of DPT-IPV and HRV vaccines, complied with the blood sampling schedule and for whom immunogenicity data was available for at least for one antigen of the DPT-IPV vaccine at Visit 7 (Month 5) sampling time point.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Co-administration Group | Anti-D and Anti-T Antibody Concentrations to Evaluate Immunogenicity | Anti-D antibody | 5.4 IU/mL |
| Co-administration Group | Anti-D and Anti-T Antibody Concentrations to Evaluate Immunogenicity | Anti-T antibody | 1.6 IU/mL |
| Staggered Group | Anti-D and Anti-T Antibody Concentrations to Evaluate Immunogenicity | Anti-D antibody | 6 IU/mL |
| Staggered Group | Anti-D and Anti-T Antibody Concentrations to Evaluate Immunogenicity | Anti-T antibody | 2 IU/mL |
Secondary
Anti-polio 1, 2 and 3 Antibodies Titers to Evaluate Immunogenicity
Titers of anti-polio 1, 2 and 3 were assessed by Neutralisation Assay (NEU) and presented as Geometric Mean Titers (GMTs). The assay cut-off was 8 ED50.
Time frame: One month post third dose of DTP-IPV vaccine (At Month 5)
Population: Analysis was performed on ATP cohort which included all subjects who complied with vaccination schedules of DPT-IPV and HRV vaccines, complied with the blood sampling schedule and for whom immunogenicity data was available for at least for one antigen of the DPT-IPV vaccine at Visit 7 (Month 5) sampling time point.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Co-administration Group | Anti-polio 1, 2 and 3 Antibodies Titers to Evaluate Immunogenicity | Anti-Polio 1 antibody | 404.7 Titer |
| Co-administration Group | Anti-polio 1, 2 and 3 Antibodies Titers to Evaluate Immunogenicity | Anti-Polio 2 antibody | 371 Titer |
| Co-administration Group | Anti-polio 1, 2 and 3 Antibodies Titers to Evaluate Immunogenicity | Anti-Polio 3 antibody | 436.3 Titer |
| Staggered Group | Anti-polio 1, 2 and 3 Antibodies Titers to Evaluate Immunogenicity | Anti-Polio 2 antibody | 470.6 Titer |
| Staggered Group | Anti-polio 1, 2 and 3 Antibodies Titers to Evaluate Immunogenicity | Anti-Polio 1 antibody | 427.9 Titer |
| Staggered Group | Anti-polio 1, 2 and 3 Antibodies Titers to Evaluate Immunogenicity | Anti-Polio 3 antibody | 409.8 Titer |
Secondary
Anti-PT and Anti-FHA Antibody Concentrations to Evaluate Immunogenicity
Concentrations of anti-PT and anti-FHA antibodies were assessed by ELISA, presented as GMCs and expressed in IU/mL. The assay cut-offs for anti-PT and anti-FHA antibody concentrations were 2.693 IU/mL and 2.046 IU/mL respectively.
Time frame: One month post third dose of DTP-IPV vaccine (At Month 5)
Population: Analysis was performed on ATP cohort which included all subjects who complied with vaccination schedules of DPT-IPV and HRV vaccines, complied with the blood sampling schedule and for whom immunogenicity data was available for at least for one antigen of the DPT-IPV vaccine at Visit 7 (Month 5) sampling time point.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Co-administration Group | Anti-PT and Anti-FHA Antibody Concentrations to Evaluate Immunogenicity | Anti-FHA antibody | 83.7 IU/mL |
| Co-administration Group | Anti-PT and Anti-FHA Antibody Concentrations to Evaluate Immunogenicity | Anti-PT antibody | 31.5 IU/mL |
| Staggered Group | Anti-PT and Anti-FHA Antibody Concentrations to Evaluate Immunogenicity | Anti-PT antibody | 31.5 IU/mL |
| Staggered Group | Anti-PT and Anti-FHA Antibody Concentrations to Evaluate Immunogenicity | Anti-FHA antibody | 97.2 IU/mL |
Secondary
Number of Subjects With Any Serious Adverse Events (SAEs)
Assessed SAEs included any untoward medical occurrence that resulted in death, was life threatening, required hospitalization or prolongation of existing hospitalization or resulted in disability/incapacity. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination.
Time frame: During the entire study period (from Day 0 to Month 5)
Population: Analysis was performed on the TVC which included all subjects with at least one dose of the study vaccines administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Co-administration Group | Number of Subjects With Any Serious Adverse Events (SAEs) | 4 Participants |
| Staggered Group | Number of Subjects With Any Serious Adverse Events (SAEs) | 5 Participants |
Secondary
Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine
Assessed solicited general AEs were fever (defined as axillary temperature ≥ 37.5 degrees Celsius \[°C\]), irritability/fussiness, diarrhoea (defined as passage of three or more looser than normal stools within a day), vomiting (defined as one or more episodes of forceful emptying of partially digested stomach contents ≥ 1 hour after feeding within a day), loss of appetite and cough/runny nose. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination.
Time frame: During the 8-day (Days 0-7) follow-up period after each dose of liquid HRV vaccine
Population: Analysis was performed on the Total Vaccinated cohort (TVC) which included all subjects with at least one dose of the study vaccines administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Co-administration Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Fever, Dose 1 | 31 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Irritability / Fussiness, Dose 1 | 66 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Diarrhoea, Dose 1 | 30 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Vomiting, Dose 1 | 19 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Loss of Appetite, Dose 1 | 18 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Cough, Dose 1 | 41 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Fever, Dose 2 | 31 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Irritability / Fussiness, Dose 2 | 61 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Diarrhoea, Dose 2 | 22 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Vomiting, Dose 2 | 14 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Loss of Appetite, Dose 2 | 17 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Cough, Dose 2 | 53 Participants |
| Staggered Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Loss of Appetite, Dose 2 | 9 Participants |
| Staggered Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Fever, Dose 1 | 32 Participants |
| Staggered Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Fever, Dose 2 | 15 Participants |
| Staggered Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Irritability / Fussiness, Dose 1 | 62 Participants |
| Staggered Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Vomiting, Dose 2 | 18 Participants |
| Staggered Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Diarrhoea, Dose 1 | 32 Participants |
| Staggered Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Irritability / Fussiness, Dose 2 | 41 Participants |
| Staggered Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Vomiting, Dose 1 | 19 Participants |
| Staggered Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Cough, Dose 2 | 45 Participants |
| Staggered Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Loss of Appetite, Dose 1 | 10 Participants |
| Staggered Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Diarrhoea, Dose 2 | 26 Participants |
| Staggered Group | Number of Subjects With Any Solicited General Adverse Events (AEs) After Each Dose of Liquid HRV Vaccine | Any Cough, Dose 1 | 40 Participants |
Secondary
Number of Subjects With Any Solicited General AEs After First Dose of DTP-IPV Vaccine
Assessed solicited general AEs were drowsiness, fever (defined as axillary temperature ≥ 37.5 °C), irritability/fussiness and loss of appetite. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination.
Time frame: During the 8-day (Days 0-7) follow-up period after first dose of DTP-IPV vaccine
Population: Analysis was performed on the TVC which included all subjects with at least one dose of the study vaccines administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Co-administration Group | Number of Subjects With Any Solicited General AEs After First Dose of DTP-IPV Vaccine | Any Drowiness | 37 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General AEs After First Dose of DTP-IPV Vaccine | Any Fever | 31 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General AEs After First Dose of DTP-IPV Vaccine | Any Irritability / Fussiness | 61 Participants |
| Co-administration Group | Number of Subjects With Any Solicited General AEs After First Dose of DTP-IPV Vaccine | Any Loss of Appetite | 17 Participants |
| Staggered Group | Number of Subjects With Any Solicited General AEs After First Dose of DTP-IPV Vaccine | Any Loss of Appetite | 18 Participants |
| Staggered Group | Number of Subjects With Any Solicited General AEs After First Dose of DTP-IPV Vaccine | Any Drowiness | 39 Participants |
| Staggered Group | Number of Subjects With Any Solicited General AEs After First Dose of DTP-IPV Vaccine | Any Irritability / Fussiness | 59 Participants |
| Staggered Group | Number of Subjects With Any Solicited General AEs After First Dose of DTP-IPV Vaccine | Any Fever | 32 Participants |
Secondary
Number of Subjects With Any Solicited Local AEs After First Dose of DTP-IPV Vaccine
Assessed solicited local AEs were pain, redness and swelling at injection site. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination.
Time frame: During the 8-day (Days 0-7) follow-up period after first dose of DTP-IPV vaccine
Population: Analysis was performed on the TVC which included all subjects with at least one dose of the study vaccines administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Co-administration Group | Number of Subjects With Any Solicited Local AEs After First Dose of DTP-IPV Vaccine | Any Pain | 32 Participants |
| Co-administration Group | Number of Subjects With Any Solicited Local AEs After First Dose of DTP-IPV Vaccine | Any Redness (mm) | 85 Participants |
| Co-administration Group | Number of Subjects With Any Solicited Local AEs After First Dose of DTP-IPV Vaccine | Any Swelling (mm) | 50 Participants |
| Staggered Group | Number of Subjects With Any Solicited Local AEs After First Dose of DTP-IPV Vaccine | Any Pain | 24 Participants |
| Staggered Group | Number of Subjects With Any Solicited Local AEs After First Dose of DTP-IPV Vaccine | Any Redness (mm) | 84 Participants |
| Staggered Group | Number of Subjects With Any Solicited Local AEs After First Dose of DTP-IPV Vaccine | Any Swelling (mm) | 44 Participants |
Secondary
Number of Subjects With Any Unsolicited AE After First Dose of DTP-IPV Vaccine
Unsolicited AEs were defined as any AE reported in addition to those solicited during the clinical study and any solicited AE with onset outside the specified period of follow-up for solicited AEs. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination.
Time frame: During the 31-day (Days 0-30) follow-up period after first dose of DTP-IPV vaccine
Population: Analysis was performed on the TVC which included all subjects with at least one dose of the study vaccines administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Co-administration Group | Number of Subjects With Any Unsolicited AE After First Dose of DTP-IPV Vaccine | 65 Participants |
| Staggered Group | Number of Subjects With Any Unsolicited AE After First Dose of DTP-IPV Vaccine | 59 Participants |
Secondary
Number of Subjects With Any Unsolicited AEs After Each Dose of Liquid HRV Vaccine
Unsolicited AEs were defined as any AE reported in addition to those solicited during the clinical study and any solicited AE with onset outside the specified period of follow-up for solicited AEs. Any = occurrence of the symptom regardless of intensity grade or relation to vaccination.
Time frame: During the 31-day (Days 0-30) follow-up period after each dose of liquid HRV vaccine
Population: Analysis was performed on the TVC which included all subjects with at least one dose of the study vaccines administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Co-administration Group | Number of Subjects With Any Unsolicited AEs After Each Dose of Liquid HRV Vaccine | 88 Participants |
| Staggered Group | Number of Subjects With Any Unsolicited AEs After Each Dose of Liquid HRV Vaccine | 81 Participants |
Secondary
Percentage of Seropositive Subjects for Serum Anti-rotavirus (Anti-RV) Immunoglobulin A (IgA) Antibodies in a Sub-cohort of Subjects
A seropositive subject for serum anti-RV IgA antibodies was defined as a subject with anti-RV IgA antibody concentration ≥ the seropositivity cut-off value of 20 units per milliliter (U/mL). Immunogenicity of the liquid HRV vaccine in terms of serum anti-RV IgA antibody seropositivity was assessed in a sub-cohort of subjects (HRV immunogenicity sub-cohort) which included the first 73 subjects enrolled into each of the 2 study groups.
Time frame: One month post second dose of liquid HRV vaccine (At Month 2 for the Co-administration Group and at Month 2.5 for the Staggered Group)
Population: Analysis was performed on HRV immunogenicity sub-cohort of ATP cohort which included all subjects who complied with vaccination schedules of DPT-IPV and HRV vaccines, complied with the blood sampling schedule and for whom immunogenicity data was available for at least for one antigen of the DPT-IPV vaccine at Visit 7 (Month 5) sampling time point.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Co-administration Group | Percentage of Seropositive Subjects for Serum Anti-rotavirus (Anti-RV) Immunoglobulin A (IgA) Antibodies in a Sub-cohort of Subjects | 92.8 Percentage of subjects |
| Staggered Group | Percentage of Seropositive Subjects for Serum Anti-rotavirus (Anti-RV) Immunoglobulin A (IgA) Antibodies in a Sub-cohort of Subjects | 92.5 Percentage of subjects |
Secondary
Serum Anti-RV IgA Antibody Concentration to Evaluate Immunogenicity in a Sub-cohort of Subjects
Concentration of serum anti-RV IgA antibody was assessed by Enzyme Linked Immunosorbent Assay (ELISA) and expressed as geometric mean concentration (GMC) in U/mL. The assay cut-off was 20 U/mL. Immunogenicity of the liquid HRV vaccine in terms of serum anti-RV IgA antibody GMC was assessed in a sub-cohort of subjects (HRV immunogenicity sub-cohort) which included the first 73 subjects enrolled into each of the 2 study groups.
Time frame: One month post second dose of liquid HRV vaccine (At Month 2 for the Co-administration Group and at Month 2.5 for the Staggered Group)
Population: Analysis was performed on HRV immunogenicity sub-cohort of ATP cohort which included all subjects who complied with vaccination schedules of DPT-IPV and HRV vaccines, complied with the blood sampling schedule and for whom immunogenicity data was available for at least for one antigen of the DPT-IPV vaccine at Visit 7 (Month 5) sampling time point.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Co-administration Group | Serum Anti-RV IgA Antibody Concentration to Evaluate Immunogenicity in a Sub-cohort of Subjects | 350.1 U/mL |
| Staggered Group | Serum Anti-RV IgA Antibody Concentration to Evaluate Immunogenicity in a Sub-cohort of Subjects | 362.5 U/mL |